×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Exchange
/
Drug Targets
🎯 Drug Targets
Browse 3 drug targets with druggability analysis, composite scores, and clinical context
3
Targets
0
High Druggability
0.46
Avg Score
15
Target Classes
Druggability Distribution
High:
0
Medium:
0
Low:
3
Unknown:
0
Avg druggability score:
0.359
Clinical Pipeline
Approved:
0
Phase III:
0
Phase II:
2
Phase I:
1
Preclinical:
0
Total compounds:
8
· Approved:
0
Search
Class
All Classes
Enzyme
(35)
Signaling Protein
(25)
Structural Protein
(17)
Protein
(16)
Gpcr
(13)
Ion Channel
(12)
Transcription Factor
(11)
Receptor
(11)
Ligand
(10)
Transporter
(8)
Epigenetic Regulator
(8)
Kinase
(7)
Protease
(4)
Other
(4)
Chaperone
(4)
Druggability
All Druggability
Low
(100)
Medium
(62)
High
(14)
Undruggable
(6)
other
(3)
Sort
Score
Druggability
Gene A-Z
Market Price
Filtered by: class=transporter, druggability=Low — 3 results
SLC16A1
Monocarboxylate transporter 1 (MCT1)
Phase 2
Transporter
Low Druggability
Score
0.59
Drug.
0.38
Safety
0.55
Drugs
3
Hyps
1
Papers
4
Transporter modulation — restoring MCT1/MCT4 balance to normalize astrocyte-neuron metabolic coupling
SLC16A2
Monocarboxylate transporter 8
Phase 1
Transporter
Low Druggability
Score
0.43
Drug.
0.39
Safety
0.70
Drugs
1
Hyps
1
Papers
31
Substrate supplementation or transporter modulation
TRAK1_KIF5A
Trafficking kinesin protein 1 / Kinesin family mem
Phase 2
Transporter
Low Druggability
Score
0.36
Drug.
0.31
Safety
0.20
Drugs
4
Hyps
1
Papers
28
Therapeutic approaches targeting TRAK1_KIF5A aim to restore or enhance axonal mitochondrial transport by either stabilizing the KIF5A motor protein complex, reducing mutant protein expression through antisense oligonucleotides, or replacing defective protein via gene therapy. This restores cellular energy homeostasis and reduces neuronal degeneration in motor neurons.